EP1986685A4 - Zusammensetzungen zur ausgabe eines impfstoffs und anwendungsverfahren dafür - Google Patents

Zusammensetzungen zur ausgabe eines impfstoffs und anwendungsverfahren dafür

Info

Publication number
EP1986685A4
EP1986685A4 EP07762672A EP07762672A EP1986685A4 EP 1986685 A4 EP1986685 A4 EP 1986685A4 EP 07762672 A EP07762672 A EP 07762672A EP 07762672 A EP07762672 A EP 07762672A EP 1986685 A4 EP1986685 A4 EP 1986685A4
Authority
EP
European Patent Office
Prior art keywords
methods
delivery compositions
vaccine delivery
vaccine
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07762672A
Other languages
English (en)
French (fr)
Other versions
EP1986685A2 (de
Inventor
William Turnell
Kristin Defife
Maria A Vitiello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivas LLC
Original Assignee
Medivas LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/003575 external-priority patent/WO2006088647A1/en
Priority claimed from US11/345,021 external-priority patent/US20060188469A1/en
Priority claimed from US11/344,689 external-priority patent/US20060177416A1/en
Priority claimed from PCT/US2006/003412 external-priority patent/WO2006083874A2/en
Priority claimed from US11/345,815 external-priority patent/US20060188486A1/en
Priority claimed from US11/636,230 external-priority patent/US20070160622A1/en
Application filed by Medivas LLC filed Critical Medivas LLC
Publication of EP1986685A2 publication Critical patent/EP1986685A2/de
Publication of EP1986685A4 publication Critical patent/EP1986685A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
EP07762672A 2006-01-31 2007-01-31 Zusammensetzungen zur ausgabe eines impfstoffs und anwendungsverfahren dafür Withdrawn EP1986685A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
PCT/US2006/003575 WO2006088647A1 (en) 2005-02-17 2006-01-31 Polymer particle delivery compositions and methods of use
US11/345,021 US20060188469A1 (en) 2003-10-14 2006-01-31 Vaccine delivery compositions and methods of use
US11/344,689 US20060177416A1 (en) 2003-10-14 2006-01-31 Polymer particle delivery compositions and methods of use
PCT/US2006/003412 WO2006083874A2 (en) 2005-02-01 2006-01-31 Vaccine delivery compositions and methods of use
US11/345,815 US20060188486A1 (en) 2003-10-14 2006-02-01 Wound care polymer compositions and methods for use thereof
US84242306P 2006-09-05 2006-09-05
US85817306P 2006-11-10 2006-11-10
US11/636,230 US20070160622A1 (en) 2005-12-07 2006-12-07 Method for assembling a polymer-biologic delivery composition
PCT/US2007/002704 WO2007089870A2 (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use

Publications (2)

Publication Number Publication Date
EP1986685A2 EP1986685A2 (de) 2008-11-05
EP1986685A4 true EP1986685A4 (de) 2009-02-25

Family

ID=56290916

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07762672A Withdrawn EP1986685A4 (de) 2006-01-31 2007-01-31 Zusammensetzungen zur ausgabe eines impfstoffs und anwendungsverfahren dafür

Country Status (4)

Country Link
EP (1) EP1986685A4 (de)
JP (1) JP2009525341A (de)
CA (1) CA2676601A1 (de)
WO (1) WO2007089870A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
EP1933881B1 (de) 2005-09-22 2019-03-13 Medivas, LLC Feste polymer-abgabezusammensetzungen und anwendungsverfahren dafür
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
PT2347775T (pt) 2005-12-13 2020-07-14 The President And Fellows Of Harvard College Estruturas em andaime para transplante celular
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
BRPI1011836A2 (pt) * 2009-04-21 2017-05-16 Selecta Biosciences Inc imunonanoterapêuticos que fornecem uma resposta induzida por th1
US20110020388A1 (en) * 2009-05-27 2011-01-27 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EA023397B1 (ru) 2010-05-26 2016-05-31 Селекта Байосайенсиз, Инк. Комбинированные вакцины с синтетическими наноносителями
EP2575869B1 (de) * 2010-06-04 2017-07-26 Flow Pharma Inc. Peptidpartikelformulierung
WO2012048165A2 (en) 2010-10-06 2012-04-12 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
EP2723800B1 (de) 2011-06-23 2015-10-07 DSM IP Assets B.V. Mikro- oder nanopartikel mit einem biologisch abbaubaren polyesteramid-copolymer zur verwendung bei der verabreichung von bioaktiven substanzen
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
CA2870309C (en) 2012-04-16 2024-02-20 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
DE102015109996B3 (de) * 2015-06-22 2016-07-28 Gerresheimer Regensburg Gmbh Einrichtung zum Öffnen von Kapseln
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
CN115305229A (zh) 2016-07-13 2022-11-08 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
WO2023032891A1 (ja) * 2021-08-30 2023-03-09 東レ株式会社 免疫原性増強用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083874A2 (en) * 2005-02-01 2006-08-10 Medivas, Llc. Vaccine delivery compositions and methods of use
US20060188469A1 (en) * 2003-10-14 2006-08-24 Medivas, Llc Vaccine delivery compositions and methods of use
WO2007067744A2 (en) * 2005-12-07 2007-06-14 Medivas, Llc Method for assembling a polymer-biologic delivery composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4224499A (en) * 1998-05-29 1999-12-13 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188469A1 (en) * 2003-10-14 2006-08-24 Medivas, Llc Vaccine delivery compositions and methods of use
WO2006083874A2 (en) * 2005-02-01 2006-08-10 Medivas, Llc. Vaccine delivery compositions and methods of use
WO2007067744A2 (en) * 2005-12-07 2007-06-14 Medivas, Llc Method for assembling a polymer-biologic delivery composition

Also Published As

Publication number Publication date
EP1986685A2 (de) 2008-11-05
CA2676601A1 (en) 2007-08-09
JP2009525341A (ja) 2009-07-09
WO2007089870A3 (en) 2008-05-02
WO2007089870A2 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
EP1986685A4 (de) Zusammensetzungen zur ausgabe eines impfstoffs und anwendungsverfahren dafür
EP2152293A4 (de) Zusammensetzungen zur proteinabgabe und verfahren zu deren verwendung
HK1249031A1 (zh) 疫苗施用的方法
IL202684A0 (en) Anti-cd20 therapeutic compositions and methods of use thereof
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP1973986A4 (de) Zusammensetzungen bioaktiver komplexe und verfahren zu ihrer verwendung
EP1988918A4 (de) Adjuvanz- und impfstoffzusammensetzungen
IL197275A0 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
EP2032156A4 (de) Zusammensetzungen und verfahren zur abgabe von sauerstoff
EP2271301A4 (de) Verfahren und zusammensetzungen zur abgabe von mitteln
EP2024476A4 (de) Zusammensetzungen mit nieder-dp-polymerisierten tensiden und anwendungsverfahren
HK1144787A1 (en) Anti-fmd vaccine composition and preparation and use thereof
EP2265126A4 (de) Verfahren und zusammensetzungen für die kontrollierte abgabe von phytochemikalien
ZA200807408B (en) Compositions and methods for delivery of amino-functional drugs
EP2170404A4 (de) Zusammensetzungen mit humanem egfr-sirna und anwendungsverfahren
EP2112931A4 (de) Verfahren und zusammensetzungen zur transdermalen freisetzung von nukleotiden
IL209027A0 (en) Vaccine compositions and uses thereof
EP2021448A4 (de) Zusammensetzungen mit polymerisierten tensiden mit geringem dp und verfahren zu ihrer verwendung
EP2021447A4 (de) Zusammensetzungen mit polymerisierten tensiden mit einem niedrigen polymerisationsgrad und verwendung davon
HK1151242A1 (en) Mntf peptide compositions and methods of use mntf
AU2008904468A0 (en) Vaccine composition and use of same
GB0602871D0 (en) Use Of Anti-Microbial Compositions And Novel Methods For The Delivery Of Such Compositions
GB0613428D0 (en) In situ delivery of probotic formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080828

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20090123

17Q First examination report despatched

Effective date: 20090512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090801